Nasus Pharma Ltd (NSRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 06-2025 | 12-2024 | 12-2023 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -5,805 | -1,194 | -1,552 | -1,005 |
| Accounts payable and accrued liabilities | N/A | 13 | N/A | N/A |
| Other Working Capital | -415 | 279 | 405 | 167 |
| Other Operating Activity | 1,302 | 469 | 482 | -191 |
| Operating Cash Flow | $-4,918 | $-433 | $-665 | $-1,029 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -14 | N/A | 0 | 0 |
| Other Investing Activity | -3,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-3,014 | $N/A | $0 | $0 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | N/A | 435 | N/A | N/A |
| Other Financing Activity | 8,920 | -75 | 770 | 1,055 |
| Financing Cash Flow | $8,920 | $360 | $770 | $1,055 |
| Exchange Rate Effect | -8 | -6 | -4 | 13 |
| Beginning Cash Position | 311 | 311 | 210 | 171 |
| End Cash Position | 1,291 | 232 | 311 | 210 |
| Net Cash Flow | $980 | $-79 | $101 | $39 |
| Free Cash Flow | ||||
| Operating Cash Flow | -4,918 | -433 | -665 | -1,029 |
| Free Cash Flow | -4,918 | -433 | -665 | -1,029 |